ATE270549T1 - Substituierte trizyklische pyrazolderivate mit protein kinase aktivität - Google Patents

Substituierte trizyklische pyrazolderivate mit protein kinase aktivität

Info

Publication number
ATE270549T1
ATE270549T1 AT99920103T AT99920103T ATE270549T1 AT E270549 T1 ATE270549 T1 AT E270549T1 AT 99920103 T AT99920103 T AT 99920103T AT 99920103 T AT99920103 T AT 99920103T AT E270549 T1 ATE270549 T1 AT E270549T1
Authority
AT
Austria
Prior art keywords
pyrazole
dihydro
indazole
chemical compounds
derivatives
Prior art date
Application number
AT99920103T
Other languages
English (en)
Inventor
Lee Arnold
Paul Rafferty
Michael Hockley
Allyson Turner
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Application granted granted Critical
Publication of ATE270549T1 publication Critical patent/ATE270549T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
AT99920103T 1998-04-30 1999-04-28 Substituierte trizyklische pyrazolderivate mit protein kinase aktivität ATE270549T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8364898P 1998-04-30 1998-04-30
PCT/US1999/009185 WO1999055335A1 (en) 1998-04-30 1999-04-28 Substituted tricyclic pyrazole derivatives with protein kinase activity

Publications (1)

Publication Number Publication Date
ATE270549T1 true ATE270549T1 (de) 2004-07-15

Family

ID=22179779

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99920103T ATE270549T1 (de) 1998-04-30 1999-04-28 Substituierte trizyklische pyrazolderivate mit protein kinase aktivität

Country Status (8)

Country Link
EP (1) EP1073435B1 (de)
JP (1) JP2002512962A (de)
CN (1) CN1311678A (de)
AT (1) ATE270549T1 (de)
DE (1) DE69918542T2 (de)
ES (1) ES2224650T3 (de)
PT (1) PT1073435E (de)
WO (1) WO1999055335A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2289791T3 (es) 1997-08-22 2008-02-01 Astrazeneca Ab Derivados de oxindolilquinazolina como inhibidores de la angiogenesis.
JP2002529421A (ja) * 1998-11-06 2002-09-10 ビーエーエスエフ アクチェンゲゼルシャフト 血管過浸透性の阻害方法
AU3003701A (en) * 1999-11-19 2001-05-30 Axxima Pharmaceuticals Ag Inhibitors of helicobacter pylori induced gastrointestinal diseases
US6849409B2 (en) 2000-10-16 2005-02-01 Axxima Pharmaceuticals Ag Cellular kinases involved in Cytomegalovirus infection and their inhibition
DE10134196B4 (de) * 2001-07-13 2005-08-18 Forschungszentrum Karlsruhe Gmbh Technik Und Umwelt Pharmazeutische Zusammensetzung zur Hemmung der unkontrollierten Vermehrung und/oder Induzierung der Apoptose von Zellen
ATE363473T1 (de) 2001-09-19 2007-06-15 Pharmacia Corp Substituierte pyrazoloverbindungen zur behandlung von entzündungen
BR0212841A (pt) * 2001-09-26 2004-08-03 Pharmacia Italia Spa Derivado ativo de aminoindazole como inibidores de cinase, processo para sua preparação e composições farmacêuticas que os contém
US20050176796A1 (en) * 2002-02-19 2005-08-11 D'alessio Roberto Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents
US7166293B2 (en) * 2002-03-29 2007-01-23 Carlsbad Technology, Inc. Angiogenesis inhibitors
AR045037A1 (es) 2003-07-10 2005-10-12 Aventis Pharma Sa Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
ATE481134T1 (de) * 2004-01-21 2010-10-15 Univ Emory Zusammensetzungen und verwendung von tyrosinkinase-hemmern zur behandlung von pathogenen infektionen
EP2258700A1 (de) 2006-05-09 2010-12-08 Pfizer Products Inc. Cycloalkylaminosäure Derivate und diese enthaltende Pharmazeutische Zusammensetzungen
DK2089367T3 (da) 2006-10-31 2012-02-06 Pfizer Prod Inc Pyrazolinforbindelser som mineralocorticoidreceptor-antagonister
CN101434595B (zh) * 2008-12-19 2014-06-25 沈阳药科大学 抗真菌剂-硫色满酮缩氨基(硫)脲系列物
JP2012524058A (ja) * 2009-04-15 2012-10-11 フォンダツィオーネ アイアールシーシーエス イスティトゥト ナツィオナーレ デイ トゥモリ 血管透過性亢進の治療におけるマルチキナーゼ阻害剤の使用
CN102086212B (zh) * 2009-12-03 2013-06-12 沈阳药科大学 抗真菌剂-2，3，4，5-四氢-4H-苯并[b]噻喃并[4，3-c]吡唑-2-甲酰胺衍生物
US8853207B2 (en) 2012-04-12 2014-10-07 Development Center For Biotechnology Heterocyclic pyrazole compounds, method for preparing the same and use thereof
RU2674447C1 (ru) * 2017-12-19 2018-12-10 Федеральное государственное бюджетное образовательное учреждение высшего образования "Дальневосточный государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО ДВГМУ Минздрава России) Способ лечения синдрома избыточного бактериального роста в тонком кишечнике у больных сахарным диабетом 2 типа в сочетании с гастродуоденальным хеликобактериозом
JP2023552993A (ja) * 2020-12-09 2023-12-20 ウェルスタット セラピューティクス コーポレイション 抗炎症作用、抗真菌作用、抗寄生虫作用、及び抗がん作用を有するイミダゾキノリン化合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE789948A (fr) * 1971-10-13 1973-04-11 Sandoz Sa Nouveaux derives du pyrazole, leur preparation et leur application comme medicaments
US3816437A (en) * 1972-12-22 1974-06-11 Sandoz Ag Thieno(2,3-g)indazoles
US3816438A (en) * 1972-12-22 1974-06-11 Sandoz Ag 2h(1)-benzothiepino(5,4-c)-pyrazoles and(1)-benzothiopyrano(4,3-c)-pyrazoles
US3843664A (en) * 1973-02-20 1974-10-22 Sandoz Ag Substituted naphtho pyrazoles
US3843666A (en) * 1973-05-29 1974-10-22 Sandoz Ag Process for preparing substituted indeno,naphtho and cyclohepta pyrazoles
EP0665840A1 (de) * 1992-10-23 1995-08-09 MERCK SHARP & DOHME LTD. Dopamin-rezeptor subtypliganden
US6080745A (en) * 1993-09-15 2000-06-27 Merck Sharp & Dohme Limited Fused tricyclic heteroaromatic derivatives as dopamine receptor subtype ligands
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
JP2001518501A (ja) * 1997-10-06 2001-10-16 ビーエーエスエフ アクチェンゲゼルシャフト インデノ［１，２−ｃ］−、ナフト［１，２−ｃ］−およびベンゾ［６，７］シクロへプタ［１，２−ｃ］ピラゾール誘導体

Also Published As

Publication number Publication date
EP1073435B1 (de) 2004-07-07
CN1311678A (zh) 2001-09-05
PT1073435E (pt) 2004-10-29
WO1999055335A1 (en) 1999-11-04
ES2224650T3 (es) 2005-03-01
DE69918542D1 (de) 2004-08-12
EP1073435A1 (de) 2001-02-07
DE69918542T2 (de) 2005-08-18
JP2002512962A (ja) 2002-05-08

Similar Documents

Publication Publication Date Title
ATE270549T1 (de) Substituierte trizyklische pyrazolderivate mit protein kinase aktivität
HK1049154A1 (zh) 作为酪氨酸激酶抑制剂的2-吡唑啉-5-酮
DK1051972T3 (da) Nitrogenoxiddonorsammensætning og fremgangsmåde til behandling af anale lidelser
DE69818083D1 (de) INDENO[1,2-c]-,NAPHTHO[1,2-C]-UND BENZO[6,7]CYCLOHEPTA[1,2-c]PYRAZOLDERIVATE
BG105346A (en) Pyrolopyrimidines as protein kinase inhibitors
LV12794B (lv) Farmakoloģiski aktīvi bicikliski heterocikliski amīni
IE801747L (en) Furocoumarin compositions
BR8805744A (pt) Derivados acidos carboxilicos substituidos,processos para preparar os mesmos e fungicidas para uso na agricultura ou horticultura contendo os mesmos
DK71387A (da) Terapeutisk middel til behandling af psoriasis
IT1221826B (it) Preparato per uso topico per il trattamento terapeutico dell impotentia coeundi
Ito et al. Pharmacological studies of a new non-steroidal antiinflammatory drug: 2-(5-ethylpyridin-2-yl) benzimidazole (KB-1043)
BR0108400A (pt) Agente farmacológico e método de tratamento
IT7826674A0 (it) Derivati dell'acido glicil-metil-fosfinico, loro preparazione e loro impiego.
IT8448772A1 (it) Derivati dell'etanolo loro preparazione e loro impiego come fungicidi
ATE174216T1 (de) Verwendung von l-carnitin-o-estern mit aromatischen säuren zur behandlung der dermatosen
AU756175C (en) Catalytic domain of the human effector cell cycle checkpoint protein kinase, Chk1, materials and methods for identification of inhibitors thereof
NO802030L (no) Fremgangsmaate til fremstilling av mavesyrenoeytriliserende midler, mavesyrenoeytraliserende midler og en fremgangsmaate for behandling av hypersurhet og sykdommer forbundet med dette
NL7805427A (nl) Nieuwe derivaten van ascorbinezuur, preparaat voor het regelen van het nitrosaminegehalte in met nitriet ver- duurzaamd vlees dat zo'n derivaat bevat, alsmede vlees- produkten die met een zodanig preparaat zijn behandeld.
ATE113041T1 (de) Neue halo-propargylverbindungen,ihre verwendung und verfahren zu ihrer herstellung.
IT1254521B (it) Derivati della 2-ammino-tetralina attivi sul sistema cardiovascolare
DK0509120T3 (da) Topisk anvendelse af glycosaminoglycaner til forebyggelse og behandling af sygdomme, der påvirker det cervikale vaginale område
FI840954A7 (fi) Pyratsolonijohdannaisten käyttö lipoksidaasi-inhibiittoreina paikallisen verettömyyden, sydämen rytmihäiriöiden, reumaattisten, allergisten ja astmasairauksien, turvotuksen, keuhkotulppien, ja keuhkohypertension, happimyrkytyksen j
MX26142A (es) Derivados de acido benzoico para tratar enfermedades relacionadas con leucotrieno.
IT1090352B (it) Acidi ftalamici e acidi nicotinici e loro uso come regolatori della crescita delle piante
DK178489D0 (da) Anthralin-sterol-komplekser, deres fremstilling og anvendelse

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1073435

Country of ref document: EP

REN Ceased due to non-payment of the annual fee